Bio-Path Holdings, Inc. Announces Clinical Support Agreement with ACORN
Published: Apr 21, 2009
HOUSTON--(BUSINESS WIRE)--Bio-Path Holdings, Inc. (OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today the Company entered into an agreement with ACORN CRO, a full service, oncology-focused clinical research organization (CRO), to provide Bio-Path with a contract medical officer and potentially other clinical trial support services. Concurrent with signing the agreement, Bradley G. Somer, M.D., will serve as Bio-Path’s Medical Officer and medical liaison for the conduct of the Company’s upcoming Phase I clinical study of liposomal Grb-2 in refractory or relapsed Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL) and Myelodysplastic Syndrome (MDS).